Member Info for RichKen

GAZALA69, in my many meetings this week in the small talk, I had very similar discussions. In fact most people have very little understanding of how a test works or what is involved. They are all hoping for a vaccine. But asked would you be happy to be one of the first to have it, there is a universal NO Thanks! Then what about a test with results in less than 10 minutes, potentially less than 5 minutes using a small amount of saliva. Most think that would be the answer to removing the need for PPE masks and shields. But in the work place the question that business leaders have is what will the cost be?
So the point is, short term production cost and development costs will require a strong price, however as time goes on and more and more LFD manufacturers take up the production partnerships opportunities with Avacta and sales become truly global the price will drop dramatically, but revenue due to numbers will continue to grow.
The next point most say, that knowing me, I must have an investment interest! Then the introduction to Avacta and it’s multiple revenue opportunities as well as the potential targeted chemotherapy solutions going for phase 1 clinical testing in the next 6 months and interest is immediate.
Cheers Rich

Alltorque, of course I am a ‘nice guy’! I am invested here and BMN heavily. I have multiple business projects going on currently and my time is much more limited.
I tell you that I am delighted with the progress Alastair Smith is making here and keeping investors up to speed as developments are unfolded. His positivity in the directors talk interview was very clear. The POC laterial flow test looks like it s going to be as good if not better than expected. I truly expect strong market appreciation once the test goes on sale for several years here.
With respect to BMN I am still invested and I have made clear I sold 80% of my holding at a crucial time to invest in Covid19 stocks, however, Avacta came to my attention because of the potential chemotherapy treatment and that potential remains the biggest long term gain for Avacta. I happen to think now is a truly incredible time to add to Bushveld Minerals, they have a huge story and making good on every potential. They have a massive potential to grow quickly, they have a broker target 6 times higher than the current SP and they are hugely profit making. But, AIM doesn’t like them. But a great time to buy both in my opinion.
Run out of time!
Cheers Rich

Well CaptinStainley, my thought is BAMS production and results may well be the next RNS. I expect this within the next few days! I think it really is due.
This was always going to be the first to market. At is is though I sincerely believe there will not be much time between the release of both testing systems.
I have to say, I don't think today the market has understood fully the implication of todays news, the SP although had a usual instant spike but only small, then recovered to where is was, and then in the final moments are bunch of MM decided to drop the SP into the close. Maybe tomorrow morning we will see another quick recovery!
Something is going to happen soon we are not about to start production of millions of LFD POC tests per week and not think they are going to be possibly the very best test on the market and not expect to see a huge take up on immediate delivery orders as well as forward orders. That might be our £4 to £5 day?
Cheers, Rich

Not gone anywhere PL75. Just a very busy man!
Delighted with today’s RNS. Just another step towards real value and progress towards the worlds two most important testing systems for Covid19.
My investment and my belief in the opportunity and potential for Avacta remains more than intact. The journey is progressing very well.
Cheers Rich

For me, the position we now find the company in, is that we have two tests effectively ready for market, validation and optimisation are in progress or virtually completed. The progress now is with finalising the right manufactures and production capacities with the right costs. They may even be ahead of this. But, if both the BAMS and POC LFT are as good and simple as they should be. Then when they announce to the world global orders should come flying in and the quantities will be vast. So I expect the business to be getting everything ready before making the huge announcement to the market.
I am extremely confident that we will see two very significant announcements very soon. They will be a catalyst to a rapid growth of opportunities for Avacta in the world of diagnostics. But more importantly they will help accelerate the growth of the business in the therapeutics business which will get a very significant global opportunity and publicity.
Viruses and cancer are not going away and Avacta has the ability to make a huge difference and contribution to the fight and Affimer technology will be a major success.
In the meantime small percentage buys and sells at strategic opportunities are helping my portfolio of Avacta shares grow day by day.
But one of theses days Avacta will put out an RNS during the day and we will rocket!
I am keeping the faith and patience will be rewarded.
Have a good day all! I agree with Ophidian a blue day!
Cheers Rich.

Mortgagefreeman, thanks for asking, I have gone nowhere. I am awaiting the next news which will be the BAMS update, then new partnerships and then the big one the LFD RNS.
I have multiple business projects which are taking all my time. I am keeping a broad view of progress and the current situation and making the most of opportunities.
The current drop was inevitable given no news but I would not be surprised to see this blue before the day is out. BAMS is due very soon and could come at anytime. When it does expect a very decent jump into the £2 plus holding point. By the end of August, I would be surprised if we are not close the £4. Sales through September may see another spike. But, one step at a time.
My holding now exceeds 750k shares and that is a very good hold for me. My portfolio building is now quietly on some new projects which I expect to make strong gains in the future.
Avacta is a long term hold for me and I expect to hold for 2 to 3 years minimum or until a buyout if that happens.
Anyway cheers all and let’s hope for a strong afternoon!
Rich

Finally the government are seeing sense and easing of restrictions is being halted. The situation is on a knife edge. They need the economy operational and want people to have a holiday, but it is like a path straight back to disaster and a huge spike. If people don’t take precautions seriously, then we are very likely to see multiple lockdowns in towns and cities.
I am sure we all agree that our tests cannot come soon enough.
Cheers Rich

No he continues to hold and grow his position!

I found Avacta via a recommendation from a very good friend. My timing arriving was at the early part of April as ‘Themuir’ will remember. I bought in at 38p with a significant buy and then really built my position in the 70p range.

My reason was the targeted chemotherapy treatment, as my wife had a torrid time last year as many who follow my posting history will well know. I held a short term holding in NYCT from £1.10 adding to £2.20 and sold almost my entire holding at £4.80.
I do actually hold a few still in NYCT. But it is a token as I still see the amazing job they have done. My holding here will be a long term one, unless there is a buyout!
Cheers
Rich

On this question, I can tell you all that medical waste is incinerated to ensure that there is not risk of infection carryover and the burning plastic content is used to create heat energy for power creation at various sites in the UK.
Recycling of potentially Covid19 contaminated plastic is not desirable as they plastic would be washed before recycling and that means Covid19 contaminated water!
Hope this explains how medical waste is treated.
Cheers Rich

http://www.ip-korea.org/community/release_view.php?board=press&seq=2831&s_keywords=daewoong

It seems progress is already underway with a therapeutic!

Cheers Rich

Today announcement is surely another major step forward. Developing this partnership with a relatively small pharmaceutical company like Daewoong, gives both companies a first move advantage. They build and develop the therapy out of the main giants and build a product which could be highly valuable without the cross overs found in other large Pharmaceutical giants. With this opportunity they can feel-something truly live changing and present it to the world hopefully within a patent which will make it very valuable indeed. South Korea will have exposure to potentially different mutations of the virus to the one in Europe and the combinations could prove invaluable.


Dr. Alastair Smith, Chief Executive of Avacta Group commented:

“I am very pleased to have extended our collaboration and license agreement with Daewoong Pharmaceutical to include the SARS-COV-2 neutralising Affimer molecules for the treatment of COVID-19 and to create the potential to respond very rapidly in future to global virus threats.

AffyXell will address the need over the coming years for advanced stem cell therapies to treat lung damage caused by cytokine release syndrome suffered by COVID-19 patients and, at the same time, help prevent disease progression in these patients through the action of a neutralising Affimer therapy.

More broadly, one of the key areas of unmet clinical need that AffyXell can address with its next-generation mesenchymal stem cell therapies is acute pulmonary diseases such as COPD and acute respiratory distress syndrome. We, and our partners in South Korea, are very excited by the potential to develop life improving treatments for patients with these serious respiratory diseases as well as COVID-19.

I look forward to further updating the market on progress in our ground-breaking programmes with AffyXell in due course, and on progress with our COVID-19 diagnostics programmes shortly.”

Seng-ho Jeon, CEO of Daewoong Pharmaceutical and AffyXell Therapeutics, commented:

“It is very encouraging that AffyXell now has the opportunity to expand the application of its next-generation stem cell platform technology to target viruses. The SARS-COV-2 neutralising Affimer to be developed in combination with AffyXell’s cell and gene technology is expected to be an innovative solution for COVID-19 patients suffering cytokine release syndrome.

Daewoong has been also conducting several research programs and clinical trial for COVID-19. As the COVID-19 crisis has caused great difficulties worldwide, we will continue to focus our efforts to develop a novel therapeutic agent for COVID-19.”

I think this will just add a lot more weight to our future and this partnership may prove to be something very good indeed. The jigsaw pieces are coming together beautifully.

Cheers, Rich

No he is not. Any CEO worth their credibility would not do that. Especially if they have ambitions for a future FTSE listing.

Sorry to spoil your fun Foolishnewbie.

Cheers, Rich

So they want to charge £150 per test! Ouch.
So if mass testing is provided by a POC LFT which costs around £10 on departures and £10 on arrivals and keeps the airport open and the world safe then £20 is very cost effective.
If the airports charge £150 per test, then people will just not fly. Imagine added £300 per person to your flight cost!
The airports need the right product at the right cost and they need speed. Queuing at airports are yet another social distancing concern. They need the right test and I am sure Avacta will soon be supplying one!
Cheers Rich

I am sorry to say this, but I really don’t expect our BAMS or POC test to be anything but a complete success. The only thing that could stop us is a meteorite hitting the earth! I am not aware of one coming yet.
Not sure if this will help anyone who has fears of everything they invest in failing! But, all signs are super positive!
Cheers Rich

It is interesting how the ebb and flow of the market makers has changed in the last few days. The normal substantial drop has reduced. As normal the MM make it almost impossible now to sell any stock in the immediate moments after opening - totally many were locked out of selling for 15 to 30 minutes by which time the sell had dropped from 148 to 145. However, very quickly the price rose back up and then stayed strong in the 148/150 range for the rest of the day, with what appears strong buying into the end of the day.
Why highlight this now? Well the sentiment has changed, this has gone from a standard pattern to the point where it is showing a strong sign it is going to rise and the market markers now that time is running out before a very significant RNS which will see a big jump not only in the SP but in the market being that this is a company which is not just a strong buy for a PI, but a strong buy for much larger investors. The confirmation of our expectations here are going to drive the price up very quickly. The situation is there are many Covid19 tests on the market but none are able to give what is really needed to make it simple, no swab, no pain, no error and low cost, any time and place any where!
Avacta Share holders here know the situation inside out, and we are pretty clear that the market is going to grow from 500,000 test per day to 20 million tests per day being needed very quickly and the total market is way higher than that. The revenue for this test is truly going to be huge providing everything is right and given the picture presented by the company we have no reason not to expect top S&S results. As I have suggested previously what made the rabbit out of the hat is the point that the result maybe much faster than the 10 minutes initially suggested. If that is the case, then Avacta in reality have nobody close in the race for the gold standard Covid19 Test on the planet!
With this in mind and the multiple other revenue streams coming through to Avacta in the months ahead, with the current travel situation as well as the growth of the virus and the shots across the planet of an acceleration of the virus spread then our product as well as the potential of the virus neutralising project is going to be super valuable.
The time is coming soon and I don't now when but we are going to have one heck of an RNS and our market cap is going to jump to a level we are all going to be surprised by. I think many are know expecting a very strong growth in the next 3 months.
Rightly so! I have no intention of selling any shares here for many months to come!
Have a great evening all!
Cheers, Rich

Germany, has already announced compulsory testing for travellers returning from some countries. The testing for air travel should be at checkin and on arrival to ensure all those travellers through hub airports are captured. Global air travel still surely is one of most high risk infection points with so many people in one confined space.
If governments and airlines don’t take this on, they are never going to prevent the virus spreading from country to country if they get to zero cases. Test and isolation is the only way.
Cheers Rich

Exclusivity deals for the POC or BAMS tests are in nobodies interest. We need only to subcontract manufacturing in different continents where possible and help those clients maximise production capacities, based on returns on investment. Avacta should already have information on capacities from each potential partner and intern the partners will need to know production forecasts. This will come from research from the commercial team who will be asking around the world what take up they would have for such a product based on the provisional S&S detail and the expected test result time. They will not want to release the information to the public domain until all this is in place as it would be commercially sensitive. That is why there is this quiet time. Investors have to wait this out. But when those points are all clear then Avacta can release the news. Of course once the CONDOR results are out this will be either released immediately or Avacta may ask for the information to be held until they are ready.
But, when this news comes it should have a huge impact.
Cheers Rich

If we see what we are expecting from this amazing new Covid19 test using a small saliva sample it will be:
- The most accurate and reliable POC test
- The fastest results
- The lowest cost
- The fastest selling Covid19 test in the world
- The only one the world needs, any time and any place
Those are my expectations and the potential returns for Avacta are likely to be interesting!
My thought for the day!
Have a good one and keep safe!
Cheers Rich

Indy, thanks for your kind words.
All investors know that one persons opinion is just that. It is an opinion. We don't know for sure what is going to happen next, what discoveries will be made and their impact. We have history and we have potential. When investing you have to consider the likely hood.
Look at Amazon, who would have thought a book seller would turn into the biggest online shop in the world. Who new that some crazy American who decided to put an electric motor into a Lotus Elise would end up with the worlds most valuable automative and battery manufacturers on the plant.
When it comes to company potential we can share thoughts and ideas and come up with potential models. But the reality is rarely the model.
I have mainly been sharing what the company has said and sometimes I have looked at what could be achieved and where that may lead.
I have always had a positive outlook on life and it it is easier to smile and be happy than it is to be down and miserable, even in adversity if we have a positive outlook then we have a much better position. In business I expect to succeed because I have the best products and I know they work. That is the best place to be. Be sure you have the best product, the best information and you have down your diligence on the situation and its potential.
That is why I am happy with Avacta and what it can achieve. We now await the results of hard work by the company and some nifty research by investors. Right product, huge market need, strong potential revenue.
Cheers, Rich

Even if the there were multiple vaccines made available tomorrow, they only deal with the virus in todays state. Look at the flu vaccine it has to be modified every year. The role our for a vacinne takes years and you need billions of doses and the take up has to be huge.
The need for testing will be with us for a minimum of 18 maybe even 24 months. Once our POC test is completed, validated and for sale, you can be sure that Avacta and Cytiva will be making changes to move around any virus mutations and they will be able to do this very quickly, keeping the virus in check as the most import point which has been made by the WHO from the beginning you need to test and isolate. This is the only way to prevent the virus spreading. Even with a perfect vaccine, many will not trust it and refuse it. So testing will be with us for a very long time.
The other point to consider is that Avacta will not just produce one type of LFT and sit back. They will be looking at multiple other viruses and deceases which there new tech can be used on. I would expect to see over the years ahead many new tests coming out using Affimers giving very accurate diagnosis.
So Bram, I m expecting the SP to leap upwards very soon! Please excuse the pun :-)
Cheers, Rich